Mersana Therapeutics, Inc. (MRSN) Trades at $14.86 After Triangle; Profile of 6 Analysts Covering Zillow Group, Inc. (Z)

February 14, 2018 - By Marie Mckinney

Mersana Therapeutics, Inc. (MRSN) formed triangle with $16.20 target or 9.00% above today’s $14.86 share price. Mersana Therapeutics, Inc. (MRSN) has $338.12 million valuation. The stock increased 5.46% or $0.77 during the last trading session, reaching $14.86. About 94,042 shares traded or 25.34% up from the average. Mersana Therapeutics, Inc. (NASDAQ:MRSN) has 0.00% since February 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 10 analysts covering Zillow Inc (NASDAQ:Z), 6 have Buy rating, 0 Sell and 4 Hold. Therefore 60% are positive. Zillow Inc had 26 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Zillow Group, Inc. (NASDAQ:Z) earned “Buy” rating by Stifel Nicolaus on Tuesday, February 14. The company was maintained on Wednesday, August 5 by Benchmark. The firm has “Market Perform” rating by Cowen & Co given on Wednesday, May 4. Stifel Nicolaus initiated the shares of Z in report on Thursday, December 22 with “Hold” rating. RBC Capital Markets maintained the stock with “Sector Perform” rating in Wednesday, August 5 report. The firm earned “Overweight” rating on Thursday, July 14 by Morgan Stanley. Morgan Stanley maintained the stock with “Buy” rating in Wednesday, August 5 report. The rating was maintained by Cowen & Co with “Hold” on Friday, February 9. As per Wednesday, November 4, the company rating was maintained by Benchmark. The firm has “Buy” rating by Morgan Stanley given on Wednesday, January 10. See Zillow Group, Inc. (NASDAQ:Z) latest ratings:

09/02/2018 Broker: Cowen & Co Rating: Hold New Target: $47.0 Maintain
26/01/2018 Broker: KeyBanc Capital Markets Rating: Buy Upgrade
10/01/2018 Broker: Morgan Stanley Rating: Buy New Target: $50.0 Upgrade
10/01/2018 Broker: Cowen & Co Rating: Hold New Target: $45.0 Maintain
08/11/2017 Broker: Inc. – Class C Capital Stock Rating: Canaccord Genuity New Target: $52 53
22/09/2017 Broker: Canaccord Genuity Rating: Buy New Target: $52.0
05/09/2017 Broker: Oppenheimer Rating: Hold

Among 3 analysts covering Mersana Therapeutics Inc (NASDAQ:MRSN), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Mersana Therapeutics Inc had 3 analyst reports since July 24, 2017 according to SRatingsIntel. The stock of Mersana Therapeutics, Inc. (NASDAQ:MRSN) has “Buy” rating given on Monday, July 24 by J.P. Morgan. The company was initiated on Monday, July 24 by Leerink Swann. The firm has “Buy” rating given on Monday, July 24 by Cowen & Co.

Zillow Group, Inc. operates real estate and home-related information marketplaces on mobile and the Web in the United States. The company has market cap of $8.21 billion. The firm offers a portfolio of brands and products to enable people find information about homes and connect with local professionals. It currently has negative earnings. The Company’s brands focus on various stages of the home lifecycle, including renting, buying, selling, and financing.

The stock increased 1.02% or $0.45 during the last trading session, reaching $44.72. About 1.42M shares traded or 46.82% up from the average. Zillow Group, Inc. (NASDAQ:Z) has risen 50.16% since February 14, 2017 and is uptrending. It has outperformed by 33.46% the S&P500.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>